Richard C Shelton1, George I Papakostas. 1. Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA. richard.shelton@vanderbilt.edu
Abstract
OBJECTIVE: Atypical antipsychotics (AAPs) have been hypothesized to be beneficial in treatment-resistant depression (TRD). This paper will review a biochemical rationale and will summarize the data regarding the effectiveness of AAPs in TRD. METHOD: Studies were identified using searches of Pubmed/Medline, EMBase and the Cochrane databases by cross-referencing the term 'depression' with each of the six AAPs. RESULTS: After initial positive, short case reports and clinical trials, larger studies failed to show the effectiveness of AAPs combined with antidepressants for TRD. More recently, larger scale clinical trials have supported the effectiveness of at least some of these medications. While AAPs have gained in popularity for TRD, there are nagging concerns regarding risks such as metabolic syndrome and tardive dyskinesia. CONCLUSION: The existing research provides some support for the beneficial effects of AAPs when combined with SSRI's in TRD. These medications pose significant risks that must be considered in their use.
OBJECTIVE: Atypical antipsychotics (AAPs) have been hypothesized to be beneficial in treatment-resistant depression (TRD). This paper will review a biochemical rationale and will summarize the data regarding the effectiveness of AAPs in TRD. METHOD: Studies were identified using searches of Pubmed/Medline, EMBase and the Cochrane databases by cross-referencing the term 'depression' with each of the six AAPs. RESULTS: After initial positive, short case reports and clinical trials, larger studies failed to show the effectiveness of AAPs combined with antidepressants for TRD. More recently, larger scale clinical trials have supported the effectiveness of at least some of these medications. While AAPs have gained in popularity for TRD, there are nagging concerns regarding risks such as metabolic syndrome and tardive dyskinesia. CONCLUSION: The existing research provides some support for the beneficial effects of AAPs when combined with SSRI's in TRD. These medications pose significant risks that must be considered in their use.
Authors: Stevan Pecic; Pooja Makkar; Sandeep Chaudhary; Boojala V Reddy; Hernan A Navarro; Wayne W Harding Journal: Bioorg Med Chem Date: 2010-06-20 Impact factor: 3.641
Authors: Laura E Dichtel; Linda L Carpenter; Maren Nyer; David Mischoulon; Allison Kimball; Thilo Deckersbach; Darin D Dougherty; David A Schoenfeld; Lauren Fisher; Cristina Cusin; Christina Dording; Nhi-Ha Trinh; Paola Pedrelli; Albert Yeung; Amy Farabaugh; George I Papakostas; Trina Chang; Benjamin G Shapero; Justin Chen; Paolo Cassano; Emily M Hahn; Elizabeth M Rao; Roscoe O Brady; Ravinder J Singh; Audrey R Tyrka; Lawrence H Price; Maurizio Fava; Karen K Miller Journal: Am J Psychiatry Date: 2020-07-14 Impact factor: 18.112
Authors: Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca Journal: Expert Rev Neurother Date: 2017-01-29 Impact factor: 4.618
Authors: Tanya J Fabian; Zachary J Cain; Diane Ammerman; James M Eudicone; Yan Tang; Linda M Rollin; Robert A Forbes; Robert M Berman; Ross A Baker Journal: Prim Care Companion CNS Disord Date: 2012-12-20